TP53 and B-cell chronic lymphocytic leukemia: An analysis of the UMD_CLL database indicates that 91.9% of the TP53 variants identified in CLL, whether clonal or subclonal, are classified as pathogenic and 6.7% as VUS (Figure 3F).